Automated cell therapy manufacturing MoU

Ori Biotech, Cell Therapies and AdCella join forces to tackle cell therapy manufacturing challenges

Parties to work together to deploy Ori Biotech’s automated cell therapy manufacturing platform, IRO®, in Asia Pacific and across AdCella’s cellular immunotherapy pipeline

• AdAlta’s AdCella, Ori Biotech and Cell Therapies sign MoU to bring Ori Biotech’s automated cell therapy manufacturing platform, IRO®, to Australia and the Asia Pacific region.

• IRO® tackles key CAR-T challenges: high cost, slow production, and inconsistent results.

• Next-generation automation promises: 10–50x higher throughput; shorter manufacturing times; 30–50% potential cost savings.

• Collaboration supports AdCella’s “East to West” strategy to deliver scalable, cost-effective cell therapies for solid cancers for global markets.

• Positions AdCella and CTPL as leaders in advanced cell therapy manufacturing in Asia-Pacific.

The video shows how IRO workd.

AdAlta CEO, Dr Tim Oldham said:

“Our strategy depends on showing partners that our therapies are not only effective but can be manufactured at scale, cost-effectively, and transferred easily between sites. IRO® offers the potential to deliver this across multiple products in our pipeline. This MoU is the first step toward accessing this exciting technology.”

Ori Biotech CEO, Jason Foster added:

“Getting CAR-T and other cell therapies into the clinic isn’t the biggest challenge anymore—it’s making them commercially viable. Current processes are too expensive and too hard to scale meaning that only 5% of patients globally get access to these life saving cell therapies. IRO® represents the new standard in manufacturing technology, enabling flexibility and automation from R&D all the way through to GMP. We’re thrilled to work with AdCella and CTPL to bring IRO® to Australia and the broader Asia Pacific Region.”

CTPL CEO, Dr Bev Menner said:

“Access to IRO® will help us attract commercial CAR-T programs to Australia and Asia, and accelerate development of scalable, lower cost therapies, improving patient access to these groundbreaking therapies.”